Leaders Gather for Chronic Disease Day in Dallas and DC
|
Pegasus Park opened its doors to industry professionals and executives as Good Days hosted their Healthcare Leadership Luncheon aimed at raising awareness and advocacy for rare disease. The event explored innovative strategies to enhance healthcare access and provided insights on fostering community partnerships.
Good Days is dedicated to ensuring no one has to choose between access to care and everyday necessities. The Good Days' vision aligns closely with that of BioNTX: to create a world where everyone has access to care, resources, and more good days.
|
Clinical Trial Infrastructure: A Blueprint for Future Breakthroughs
|
Panthera BioSolutions Advances North Texas Talent Pipeline
with GMP Pharmaceutical Training Course
|
The Biotechnology and Healthcare Industry Alliance of North Texas announces the successful launch of their fast-paced Pharmaceutical GMP training course. The recently launched training course is the latest product of a partnership venture facilitated by BHIANT and BioNTX, The joint venture Between Panthera BioSolutions and Dallas College is poised to elevate North Texas' biotechnology and healthcare workforce to the Top.
|
TRIBEC Summit Heralds the Future of Workforce Talent in Texas
|
Representatives from the BHIANT and other academic institutions from across the State recently met in College Station for the Texas Regional Industrial Biomanufacturing Education Certification (TRIBEC) Summit. The Summit brought industry and state leaders, educators, and economic development representatives to discuss the TRIBEC program curriculum and the future of industry workforce training in Texas. The news comes on the heels of collaborative efforts across the State that have simultaneously catapulted several cities to the national spotlight in workforce training and talent pipeline development.
|
FDA's Priority Review Vouchers:
Boosting Rare Pediatric Drug Development
|
The FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program incentivizes therapeutics development for rare pediatric diseases. If a sponsor receives approval for a drug or biologic intended to treat a rare pediatric disease, they may qualify for a PRV which grants the ability to receive priority review- significantly accelerating the FDA process.
|
How Innovation Districts Are Transforming North Texas
into a Life Science Powerhouse
|
Speaking on a recent Southwestern Medical Foundation Learning from Learners podcast, Lili Clark and Cullum Clark explored the economic transformation of North Texas through innovation districts. Tune in to hear how these districts are reshaping the Dallas-Fort Worth area and learn unique perspectives on growth and leadership for the future of the region.
|
2024 Excellence in Healthcare Awards Nominations Now Open
|
D CEO and D CEO Healthcare announce the 2024 Excellence in Healthcare Awards, honoring outstanding executives, practitioners, and organizations in healthcare despite ongoing challenges. The program also recognizes corporate wellness initiatives across industries in North Texas. Finalists will be featured in December’s D CEO issue and at D CEO Healthcare.
|
New BioNTX Member Center Portal Now Open!
|
BioNTX is grateful to our members! We have just unveiled our newest Member Benefit, an online Member Center where members can track events, search for grants and funding, browse other members, and post job openings which directly go on the main BioNTX website! There are many other amazing features for all our members to explore.
|
AMPEL BioSolutions' ORKIDS Trial Shows Krill Oil
Supplementation Improves Lupus Symptoms
|
AMPEL BioSolutions, in collaboration with Lupus Therapeutics and Aker BioMarine, has released groundbreaking results from the ORKIDS clinical trial. The study demonstrates that Omega-3-rich Krill Oil supplementation effectively reduces disease activity in Lupus patients, normalizes Omega-3 levels, and may offer cardiovascular benefits.
|
Lantern Pharma Achieves Key Milestone for Molecular Diagnostics
in Oncology Clinical Trials
|
Lantern Pharma has announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184, A novel therapeutic in clinical development for the treatment of malignant gliomas, pancreatic cancer, and atypical teratoid rhabdoid tumors (ATRT). LP-184 has also been granted an Orphan Drug Designation by the FDA, along with a Rare Pediatric Disease Designation.
|
FDA Grants Orphan Drug Designation to ReCode Therapeutics'
Primary Ciliary Dyskinesia Candidate
|
ReCode Therapeutics announced that the FDA has granted Orphan Drug Designation for RCT1100, an investigational therapy for primary ciliary dyskinesia (PCD) caused by mutations in the DNAI1 gene. PCD, a rare genetic disorder, leads to dysfunctional cilia in the respiratory tract, causing chronic infections and severe respiratory issues. RCT1100 uses ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform to deliver DNAI1 mRNA to airway cells, restoring ciliary function.
|
New Study Data Shows UT Arlington Research Contributed
Over $225 Million to U.S. Economy
|
A new report shows that research projects at The University of Texas at Arlington contributed one quarter of a billion dollars—$226.4 million, to be exact—to the national economy through 797 vendor contracts and subcontracts between 2018 and 2022.
It is no secret that much of the external research dollars that came to UTA originated as federally-sponsored grants from organizations like the National Science Foundation, National Institutes of Health, and the Departments of Defense, Transportation, Commerce, and Energy. Additional funding came from philanthropic organizations and state and local government organizations. Always pioneering innovation, the University intends to double down and grow its research funding commitments.
|
Community Health Systems Broadens Collaboration with Cost Plus Drugs for Affordable Drug Solutions
|
Community Health Systems announces the company has expanded its partnership with Mark Cuban Cost Plus Drugs Company to source a broader range of medications at significantly lower costs. This expanded collaboration is set to address the challenges of high drug prices and enhance access to essential medications for CYH’s affiliated hospitals, offering a strategic response to the current medical cost pressures.
|
Johnson & Johnson Expands Pediatric Vision Program
After Reaching Milestone of 50 Million Served
|
Johnson & Johnson and Lions Clubs International Foundation (LCIF) announced that their Sight for Kids program has now provided eye care services to over 50 million students. The program addresses vision impairment in children, aiming to improve educational outcomes and community health across the globe. Since 2002, Sight for Kids has delivered free eye screenings, provided treatments and eyeglasses, and trained over 200,000 teachers globally.
|
Fragomen Named Top Firm in Nation on Diversity Ratings
|
Fragomen has been ranked #1 on The American Lawyer’s Diversity Scorecard for the third consecutive year. Additionally, the firm secured #2 on the 2024 Women’s Scorecard and was among the top five firms for ethnic diversity, achieving #3 for Asian American attorneys this year. Fragomen has consistently excelled in these areas since 2012.
|
Expanded RSM Partnership Strengthens Mental Health Advocacy
|
The RSM US Foundation is pleased to continue its partnership with Active Minds, helping to advance the Send Silence Packing® exhibit and support new mental health programs aimed at fostering awareness, providing education, and empowering students to seek help and advocate for mental health.
|
Welch Foundation Funds UTA Research with Grant
for New Drug Delivery Technologies
|
(Above): Junha Jeon, PhD, MS
|
The Welch Foundation is supporting innovative research at the University of Texas at Arlington (UTA) aimed at improving drug delivery methods for cancer treatment. Dr. Junha Jeon, Associate Professor of Chemistry and Biochemistry at UTA, leads the project to explore arynes, compounds that show promise in delivering medications more effectively. This research seeks to develop transition metal-free cross-coupling technologies to enhance cancer therapies.
|
UTDesign Teams Achieve Top Awards for
Innovative Designs at National Conference
|
UTDesign Capstone teams recently achieved national success at the Capstone Design Conference in Tennessee; winning 2nd place with a device designed to deliver resuscitation breaths in out-of-hospital cardiac arrest situations and improve survival rates. The team was a National Finalist for their innovative design that allows for immediate CPR initiation.
|
UT Southwestern Research Reveals New Insights on
Oral Contraceptives and Advances in CAH Treatment
|
New research from UT Southwestern Medical Center is changing our understanding of oral contraceptives; revealing significant hormone fluctuations during treatment. The research, published in the American Journal of Physiology-Endocrinology and Metabolism, shows that hormone levels in women using combination oral contraceptives fluctuate throughout cycles, hinting at new avenues for more personalized contraceptive methods and treatments for hormone disorders.
|
|
Vote Good Days for the Charity Community Choice Awards
|
National non-profit, Good Days, has been nominated for the Charity Navigator Community Choice Awards, empowering supporters to recognize and celebrate the exceptional work of top-rated charities. Vote for patients, your family, and your fellow BioNTX Members!
|
A World-Class CDMO in Our Backyard: How Swiss American
Became a Global Player in Dermatologic Therapies
|
Swiss-American CDMO applies a pharmaceutical approach to strategic development. Working with thought leaders, influencers, contract research organizations , and academic centers-of-excellence to identify market and medical needs; Swiss American CDMO combines client needs with global marketplace knowledge to position trends in a differentiated way and ensure commercial success.
Through their 134,200 sq. ft. manufacturing and 131,760 sq. ft. distribution facilities in Dallas, TX; the company provides award-winning development & manufacturing, rigorous quality and compliance, a wide variety of mixing, filling and packaging equipment, and dedicated client support.
Collaborating locally and innovating around the world, Swiss American embodies its motto: We Know Skin.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
2024 iC³ Tech Transfer Showcase Application Portal is now OPEN
Applications due on August 12, 2024
|
The Tech Transfer Showcase at the iC³ Life Science Summit provides a prime opportunity to present promising intellectual property to a select audience of industry leaders and investors, opening doors to potential collaborations and funding opportunities. All Tech Transfer Showcase applicants compete for a cash prize.
Submission Guidelines
- Application deadline August 12, 2024 at 11:59 pm
- Open to all university technology transfer offices in Texas
- Two submissions per university campus
- Applications will be reviewed by a panel of industry experts
- The top six applicants will advance to podium pitch at the annual iC3 Summit
- Winning applicants will be paired with an industry mentor to help craft and polish your presentation
|
“The Tech Transfer Showcase is an excellent example of how BioNTX is serving Texas universities and creating a strong life science ecosystem across the State of Texas,” said Jennifer Souter, Senior Licensing Associate, Texas Tech Office of Research Commercialization.
|
Ignite Health Accelerator Empowers Women Shaping Healthcare
Applications due on July 22, 2024
|
Ignite Health's Accelerator Program offers an unparalleled, immersive experience for startups. Through our Mentoring Program, entrepreneurs are paired with potential customers and investors for personalized advice and guidance. With a nationwide network of Advisors, Ignite Health brings extensive expertise and connections to support healthcare startups. Participants will engage in interactive virtual learning sessions led by industry leaders, connecting with personal advisors, investors, and healthcare experts.
|
Texas Tech Presidents' Innovative Startup Award
Applications due on July 31, 2024
|
Through these funding programs and opportunities, CPRIT grows the cancer-fighting ecosystem across Texas, providing life-extending results, and tangible economic benefits throughout the State.
|
Upcoming Events & Opportunities
|
In Vitro Diagnostic Product (IVD): Classification
Join the FDA to hear how in vitro diagnostic products (IVDs) are classified by the FDA.
July 16, 2024 | Remote
|
Dallas Impact Lunch and Learn
Join Mass Challenge for this month's Dallas Impact Lunch & Learn! During the session learn how to maximize your startup's valuation and attract investors.
July 17, 2024 | Dallas, TX
|
Building a Robust Life Science Ecosystem: The Bridge Between Research, Clinical Trials, & Manufacturing
Join BioNTX for a discussion around how clinical scale manufacturing, clinical research organizations, and patient-engaging clinicians are working together to create more opportunities for life saving cures.
July 17, 2024 | Plano, TX
|
HBA DFW at BioLabs: A Networking Event
Join HBA to connect with professionals from diverse backgrounds including pharma, biotech, healthcare, consulting, research, and more, all crucial to the healthcare industry. Forge lasting business relationships, expand your professional network, and discover new opportunities.
July 17, 2024 | Dallas, TX
|
Southern Social Collective Quarter 3 Event
Join The DEC Network to connect and network with a crew of investors, entrepreneurs, and advisors that support and boost female entrepreneurs.
July 18, 2024 | Dallas, TX
|
Inclusive Capital Summit
Join Impact Ventures for a dynamic two-part experience featuring insightful panels and app-driven workshops with local and national thought leaders from the impact finance, venture capital, policy, and private equity sectors.
July 26-27, 2024 | Dallas, TX
|
Celebrating a Decade of Innovation and Excellence in North Texas
|
BioNTX is thrilled to announce our 10th Annual iC³ Life Science and Healthcare Innovation Summit, taking place on October 3rd and October 4th at the Arlington Convention Center at the Loews Hotel.
Join us for a two-day event where the most innovative minds from North Texas, the broader Southwest region and across the United States converge. Our Summit offers a vibrant platform for the bioscience and healthcare innovation to engage in thought-provoking discussions, share groundbreaking research, and delve into emerging technologies shaping the future of healthcare and biomedicine.
|
Thank You for Your Membership & Support!
|
|
